Venous Thromboembolism (VTE) in Patients with Cancer: Epidemiology and Risk Factors

REFERENCES

• Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de, Paris 1865; 3
   Google Scholar
• Buller H. R., van Doormaal F. F., van Sluis G. L., Kamphuisen P. W. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5(Suppl. 1)246–254
   PubMedGoogle Scholar
• Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723–1729
   PubMed Web of Science ®Google Scholar
• Blom J. W., Doggen C. J., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–722
   PubMed Web of Science ®Google Scholar
• Heit J. A. Cancer and venous thromboembolism: scope of the problem. Cancer Control 2005; 12(Suppl. 1)5–10
   PubMedGoogle Scholar
• Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401–410
   PubMed Web of Science ®Google Scholar
• Rickles F. R., Levine M. N. Epidemiology of thrombosis in cancer. Acta Haematol 2001; 106: 6–12
   PubMed Web of Science ®Google Scholar
• Hansson P. O., Welin L., Tibblin G., Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. ‘The Study of Men Born in 1913’. Arch Intern Med 1997; 157: 1665–1670
   PubMed Web of Science ®Google Scholar
• Sallah S., Wan J. Y., Nguyen N. P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575–579
   PubMed Web of Science ®Google Scholar
• Sorensen H. T., Mellemkjaer L., Olsen J. H., Baron J. A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343: 1846–1850
   PubMed Web of Science ®Google Scholar
• White R. H., Zhou H., Murin S., Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005; 93: 298–305
   PubMed Web of Science ®Google Scholar
• Heit J. A., O'Fallon W. M., Petterson T. M., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245–1248
   PubMed Web of Science ®Google Scholar
• El Accaoui R. N., Shamseddeen W. A., Taher A. T. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97: 1031–1036
   PubMed Web of Science ®Google Scholar
• Cronin C. G., Lohan D. G., Keane M., Roche C., Murphy J. M. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol 2007; 189: 162–170
   PubMed Web of Science ®Google Scholar
• Chew H. K., Wun T., Harvey D., Zhou H., White R. H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458–464
   PubMed Web of Science ®Google Scholar
• Levitan N., Dowlati A., Remick S. C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285–291
   PubMed Web of Science ®Google Scholar
• Falanga A., Rickles F. R. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25: 173–182
   PubMed Web of Science ®Google Scholar
• Alcalay A., Wun T., Khatri V., et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006; 24: 1112–1118
   PubMed Web of Science ®Google Scholar
• Chew H. K., Wun T., Harvey D. J., Zhou H., White R. H. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007; 25: 70–76
   PubMed Web of Science ®Google Scholar
• Rodriguez A. O., Wun T., Chew H., Zhou H., Harvey D., White R. H. Venous thromboembolism in ovarian cancer. Gynecol Oncol 2007; 105: 784–790
   PubMed Web of Science ®Google Scholar
• Elliott M. A., Wolf R. C., Hook C. C., et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma 2004; 45: 1545–1549
   PubMed Web of Science ®Google Scholar
• Chew H. K., Davies A. M., Wun T., Harvey D., Zhou H., White R. H. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008; 6: 601–608
   PubMed Web of Science ®Google Scholar
• Blom J. W., Vanderschoot J. P., Oostindier M. J., Osanto S., van der Meer F. J., Rosendaal F. R. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4: 529–535
   PubMed Web of Science ®Google Scholar
• Wun T., Chew H. K., Zhou H., Harvey D., White R. H. Cause of death among patients with local or regional stage cancer of the breast, colon and lung who develop venous thromboembolism (VTE). Blood 2006; 108: 433a–433a
   Web of Science ®Google Scholar
• Wun T., Chew H., Zhou H., Harvey D., White R. H. Venous thromboembolism (VTE) is associated with recurrent cancer in patients with initially non-metastatic breast, lung, and colon cancer. Thromb Res 2007; 120: S175–S175
   Web of Science ®Google Scholar
• White R. H., Zhou H., Romano P. S. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90: 446–455
   PubMed Web of Science ®Google Scholar
• Prandoni P., Piccioli A., Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999; 84: 437–445
   PubMed Web of Science ®Google Scholar
• Semrad T. J., O'Donnell R., Wun T., et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106: 601–608
   PubMed Web of Science ®Google Scholar
• Piccirillo J. F., Tierney R. M., Costas I., Grove L., Spitznagel E. L., Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441–2447
   PubMed Web of Science ®Google Scholar
• Charlson M., Szatrowski T. P., Peterson J., Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251
   PubMed Web of Science ®Google Scholar
• Elixhauser A., Steiner C., Harris D. R., Coffey R. M. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8–27
   PubMed Web of Science ®Google Scholar
• Otten H. M., Mathijssen J., ten Cate H., et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164: 190–194
   PubMed Web of Science ®Google Scholar
• Lee A. Y., Levine M. N. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25: 137–145
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Lyman G. H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104: 2822–2829
   PubMed Web of Science ®Google Scholar
• Haddad T. C., Greeno E. W. Chemotherapy-induced thrombosis. Thromb Res 2006; 118: 555–568
   PubMed Web of Science ®Google Scholar
• Alkindi S., Dennison D., Pathare A. Arterial and venous thrombotic complications with thalidomide in multiple myeloma. Arch Med Res 2008; 39: 257–258
   PubMed Web of Science ®Google Scholar
• Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 2007; 131: 275–277
   PubMed Web of Science ®Google Scholar
• Palumbo A., Rajkumar S. V., Dimopoulos M. A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414–423
   PubMed Web of Science ®Google Scholar
• Kilickap S., Abali H., Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21: 3542, author reply 3543
   PubMed Web of Science ®Google Scholar
• Bennett C. L., Silver S. M., Djulbegovic B., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914–924
   PubMed Web of Science ®Google Scholar
• Wun T., Law L., Harvey D., Sieracki B., Scudder S. A., Ryu J. K. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003; 98: 1514–1520
   PubMed Web of Science ®Google Scholar
• Bohlius J., Wilson J., Seidenfeld J., et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: 708–714
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Kuderer N. M., Lyman G. H. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339–2346
   PubMed Web of Science ®Google Scholar
• Verso M., Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665–3675
   PubMed Web of Science ®Google Scholar
• Verso M., Agnelli G., Bertoglio S., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057–4062
   PubMed Web of Science ®Google Scholar
• Mismetti P., Mille D., Laporte S., et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003; 88: 67–73
   PubMed Web of Science ®Google Scholar
• Niers T. M., Di Nisio M., Klerk C. P., Baarslag H. J., Buller H. R., Biemond B. J. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 2007; 5: 1878–1882
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Kuderer N. M., Culakova E., Lyman G. H., Francis C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902–4907
   PubMed Web of Science ®Google Scholar
• Falanga A. The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 2005; 90: 149
   PubMedGoogle Scholar
• Kroger K., Weiland D., Ose C., et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17: 297–303
   PubMed Web of Science ®Google Scholar
• Chen M., Geng J. G. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) 2006; 54: 75–84
   PubMed Web of Science ®Google Scholar
• Ay C., Simanek R., Vormittag R., et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients – results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 2703–2708
   PubMed Web of Science ®Google Scholar
• Tesselaar M. E., Romijn F. P., Van Der Linden I. K., Prins F. A., Bertina R. M., Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 5: 520–527
   PubMed Web of Science ®Google Scholar
• Prandoni P., Lensing A. W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484–3488
   PubMed Web of Science ®Google Scholar
• Bona R. D., Hickey A. D., Wallace D. M. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1997; 78: 137–140
   PubMed Web of Science ®Google Scholar
• Green D., Hull R. D., Brant R., Pineo G. F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339: 1476
   PubMed Web of Science ®Google Scholar
• Gould M. K., Dembitzer A. D., Doyle R. L., Hastie T. J., Garber A. M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800–809
   PubMed Web of Science ®Google Scholar
• Hettiarachchi R. J., Smorenburg S. M., Ginsberg J., Levine M., Prins M. H., Buller H. R. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999; 82: 947–952
   PubMed Web of Science ®Google Scholar
• Smorenburg S. M., Hettiarachchi R. J., Vink R., Buller H. R. The effects of unfractionated heparin on survival in patients with malignancy–a systematic review. Thromb Haemost 1999; 82: 1600–1604
   PubMed Web of Science ®Google Scholar
• Siragusa S., Cosmi B., Piovella F., Hirsh J., Ginsberg J. S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269–277
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Levine M. N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944–1948
   PubMed Web of Science ®Google Scholar
• Lee A. Y., Rickles F. R., Julian J. A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123–2129
   PubMed Web of Science ®Google Scholar
• Sgouros J., Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol 2007; 1–10
   Google Scholar
• Altinbas M., Coskun H. S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266–1271
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Kuderer N. M., Lyman G. H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632–634
   PubMed Web of Science ®Google Scholar
• Lee A. Y. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis Mon 2005; 51: 150–157
   PubMed Web of Science ®Google Scholar